 mouse model designed to aid monoclonal antibody discovery.){kind=link}
Twist Bioscience, has introduced a new humanized transgenic (HuTg) mouse model designed to aid monoclonal antibody discovery. The addition expands the company’s existing suite of in vivo antibody discovery technologies and may offer researchers an alternative to traditional licensing-based platforms.
According to Twist Bioscience, the HuTg mouse generates robust immune responses and produces fully human antibody repertoires, potentially enabling faster identification of candidate antibodies. The company suggests that its model could accelerate lead generation timelines by offering a fee-for-service approach, which bypasses the need for separate licensing agreements that often add time and complexity to the research process.
Emily Leproust, the company’s CEO and co-founder, described the HuTg mouse as complementary to Twist’s existing DiversimAb mouse and B cell screening platforms. Humanized mouse models are commonly used in drug discovery to generate antibodies with reduced immunogenicity in human patients. By incorporating fully human immunoglobulin loci, these models can serve as platforms for identifying lead therapeutic candidates without requiring further humanization steps.